1 Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A. & Bray, F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 71, 96-108 (2017).
2 Martinez Rodriguez, R. H., Buisan Rueda, O. & Ibarz, L. Bladder cancer: Present and future. Med Clin (Barc) 149, 449-455 (2017).
3 Witjes, J. A., Bruins, H. M., Cathomas, R., Comperat, E. M., Cowan, N. C., Gakis, G. et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79, 82-104 (2021).
4 Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70, 404-423 (2020).
5 Shah, J. B., McConkey, D. J. & Dinney, C. P. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 17, 2608-2612 (2011).
6 Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
7 Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet 395, 1547-1557 (2020).
8 Sauler, M., Bazan, I. S. & Lee, P. J. Cell Death in the Lung: The Apoptosis-Necroptosis Axis. Annu Rev Physiol 81, 375-402 (2019).
9 Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25, 486-541 (2018).
10 Liu, L., Li, H., Hu, D., Wang, Y., Shao, W., Zhong, J. et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer 21, 32 (2022).
11 Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & Vandenabeele, P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15, 135-147 (2014).
12 Linkermann, A., Stockwell, B. R., Krautwald, S. & Anders, H. J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 14, 759-767 (2014).
13 Kaiser, W. J., Upton, J. W., Long, A. B., Livingston-Rosanoff, D., Daley-Bauer, L. P., Hakem, R. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368-372 (2011).
14 Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363-367 (2011).
15 Shi, J., Gao, W. & Shao, F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci 42, 245-254 (2017).
16 Gutierrez, K. D., Davis, M. A., Daniels, B. P., Olsen, T. M., Ralli-Jain, P., Tait, S. W. et al. MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1beta Independently of Gasdermin-D. J Immunol 198, 2156-2164 (2017).
17 Liu, Y., Shoji-Kawata, S., Sumpter, R. M., Jr., Wei, Y., Ginet, V., Zhang, L. et al. Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci U S A 110, 20364-20371 (2013).
18 Sousa, L., Garcia, I. J., Costa, T. G., Silva, L. N., Reno, C. O., Oliveira, E. S. et al. Effects of Iron Overload on the Activity of Na,K-ATPase and Lipid Profile of the Human Erythrocyte Membrane. PLoS One 10, e0132852 (2015).
19 Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5, 253-295 (2010).
20 Ceballos, L., Elissondo, C., Sanchez Bruni, S., Denegri, G., Lanusse, C. & Alvarez, L. Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrob Agents Chemother 55, 5861-5867 (2011).
21 Qin, Z., Ou, S., Xu, L., Sorensen, K., Zhang, Y., Hu, D. P. et al. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells. Chem Biol Drug Des 97, 1059-1078 (2021).
22 Chen, C. H., Changou, C. A., Hsieh, T. H., Lee, Y. C., Chu, C. Y., Hsu, K. C. et al. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clin Cancer Res 24, 1176-1189 (2018).
23 Tang, D., Kang, R., Berghe, T. V., Vandenabeele, P. & Kroemer, G. The molecular machinery of regulated cell death. Cell Res 29, 347-364 (2019).
24 Kayagaki, N., Stowe, I. B., Lee, B. L., O'Rourke, K., Anderson, K., Warming, S. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671 (2015).
25 Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111-116 (2016).
26 Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16, 407-420 (2016).
27 Zhao, Y. G., Codogno, P. & Zhang, H. Machinery, regulation and pathophysiological implications of autophagosome maturation. Nat Rev Mol Cell Biol 22, 733-750 (2021).
28 He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100-1111 (2009).
29 Liu, Y. & Kwiatkowski, D. J. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther 14, 174-182 (2015).
30 Zhu, G., Pei, L., Li, Y., & Gou, X. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging 12, 2132–2141 (2020).
31 Pan, Y. H., Zhang, J. X., Chen, X., Liu, F., Cao, J. Z., Chen, Y. et al. Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy. Front Immunol 12, 643282 (2021).
32 Wang, H., Bao, W., Jiang, F., Che, Q., Chen, Z., Wang, F. et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett 360, 269-279 (2015).
33 Jiang, W., He, T., Liu, S., Zheng, Y., Xiang, L., Pei, X. et al. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the beta-catenin/SIRT3 signaling pathway in cervical cancer. J Hematol Oncol 11, 139 (2018).
34 Fan, K., Wang, J., Shen, S., Ni, X., Gong, Z., Zheng, B. et al. ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth. Med Oncol 39, 64 (2022).
35 Lauer, S. & Gresham, D. An evolving view of copy number variants. Curr Genet 65, 1287-1295 (2019).
36 Shao, X., Lv, N., Liao, J., Long, J., Xue, R., Ai, N. et al. Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet 20, 175 (2019).
37 Gu, J., Berman, D., Lu, C., Wistuba, II, Roth, J. A., Frazier, M. et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12, 7329-7338 (2006).
38 Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. Neuropsychopharmacology 38, 23-38 (2013).
39 Barbieri, I. & Kouzarides, T. Role of RNA modifications in cancer. Nat Rev Cancer 20, 303-322 (2020).
40 Ma, S., Chen, C., Ji, X., Liu, J., Zhou, Q., Wang, G. et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol 12, 121 (2019).
41 Du, E., Li, J., Sheng, F., Li, S., Zhu, J., Xu, Y. et al. A pan-cancer analysis reveals genetic alterations, molecular mechanisms, and clinical relevance of m(5) C regulators. Clin Transl Med 10, e180 (2020).
42 Wiener, D. & Schwartz, S. The epitranscriptome beyond m(6)A. Nat Rev Genet 22, 119-131 (2021).
43 Boo, S. H. & Kim, Y. K. The emerging role of RNA modifications in the regulation of mRNA stability. Exp Mol Med 52, 400-408 (2020).
44 Chen, X., Li, A., Sun, B. F., Yang, Y., Han, Y. N., Yuan, X. et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol 21, 978-990 (2019).
45 Yang, X., Yang, Y., Sun, B. F., Chen, Y. S., Xu, J. W., Lai, W. Y. et al. 5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m(5)C reader. Cell Res 27, 606-625 (2017).
46 Smillie, C. L., Sirey, T. & Ponting, C. P. Complexities of post-transcriptional regulation and the modeling of ceRNA crosstalk. Crit Rev Biochem Mol Biol 53, 231-245 (2018).
47 Wang, J. K., Wang, Z. & Li, G. MicroRNA-125 in immunity and cancer. Cancer Lett 454, 134-145 (2019).
48 Kamoun, A., de Reynies, A., Allory, Y., Sjodahl, G., Robertson, A. G., Seiler, R. et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 77, 420-433 (2020).
49 Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S. et al. Defining a Cancer Dependency Map. Cell 170, 564-576 e516 (2017).
50 Taylor, A. M., Shih, J., Ha, G., Gao, G. F., Zhang, X., Berger, A. C. et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33, 676-689 e673 (2018).
51 Cognetti, F., Ruggeri, E. M., Felici, A., Gallucci, M., Muto, G., Pollera, C. F. et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23, 695-700 (2012).
52 Lehmann, J., Retz, M., Wiemers, C., Beck, J., Thuroff, J., Weining, C. et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23, 4963-4974 (2005).
53 Panteliadou, M., Giatromanolaki, A., Touloupidis, S., Destouni, E., Tsoutsou, P. G., Pantelis, P. et al. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). Urol Oncol 30, 813-820 (2012).
54 Eschrich, S. A., Pramana, J., Zhang, H., Zhao, H., Boulware, D., Lee, J. H. et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75, 489-496 (2009).
55 Mohammadi, H., Prince, A., Figura, N. B., Peacock, J. S., Fernandez, D. C., Montejo, M. E. et al. Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys 106, 496-502 (2020).
56 Lee, B. K., Tiong, K. H., Chang, J. K., Liew, C. S., Abdul Rahman, Z. A., Tan, A. C. et al. DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics 18, 934 (2017).
57 Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111, 3110-3115 (2014).
58 Rebouissou, S., Bernard-Pierrot, I., de Reyniès, A., Lepage, M. L., Krucker, C., Chapeaublanc, E. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science translational medicine 6, 244ra91 (2014).
59 Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D. et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171, 540-556 e525 (2017).
60 Mo, Q., Nikolos, F., Chen, F., Tramel, Z., Lee, Y. C., Hayashi, K. et al. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. J Natl Cancer Inst 110, 448-459 (2018).
61 Marzouka, N. A., Eriksson, P., Rovira, C., Liedberg, F., Sjodahl, G. & Hoglund, M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 8, 3737 (2018).
62 Lai, H., Cheng, X., Liu, Q., Luo, W., Liu, M., Zhang, M. et al. Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer 149, 2099-2115 (2021).
63 Guo, C. C., Bondaruk, J., Yao, H., Wang, Z., Zhang, L., Lee, S. et al. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep 10, 9743 (2020).
64 Zhang, M., Wang, Y., Wang, Y., Jiang, L., Li, X., Gao, H. et al. Integrative Analysis of DNA Methylation and Gene Expression to Determine Specific Diagnostic Biomarkers and Prognostic Biomarkers of Breast Cancer. Front Cell Dev Biol 8, 529386 (2020).
65 Maeser, D., Gruener, R. F., & Huang, R. S. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings in bioinformatics 22, bbab260 (2021).
66 Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
67 Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18, 220 (2017).
68 Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).
69 Snyder, A. G. & Oberst, A. The Antisocial Network: Cross Talk Between Cell Death Programs in Host Defense. Annu Rev Immunol 39, 77-101 (2021).
70 Kesavardhana, S., Malireddi, R. K. S. & Kanneganti, T. D. Caspases in Cell Death, Inflammation, and Pyroptosis. Annu Rev Immunol 38, 567-595 (2020).
71 Parrish, A. B., Freel, C. D. & Kornbluth, S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol 5 (2013).
72 McIlwain, D. R., Berger, T. & Mak, T. W. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 7 (2015).
73 Kalai, M., Van Loo, G., Vanden Berghe, T., Meeus, A., Burm, W., Saelens, X. et al. Tipping the balance between necrosis and apoptosis in human and murine cells treated with interferon and dsRNA. Cell Death Differ 9, 981-994 (2002).
74 Tsuchiya, K., Nakajima, S., Hosojima, S., Thi Nguyen, D., Hattori, T., Manh Le, T. et al. Caspase-1 initiates apoptosis in the absence of gasdermin D. Nat Commun 10, 2091 (2019).
75 Sun, L., Ma, W., Gao, W., Xing, Y., Chen, L., Xia, Z. et al. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis 10, 542 (2019).
76 Maiuri, M. C., Zalckvar, E., Kimchi, A. & Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature Reviews Molecular Cell Biology 8, 741-752 (2007).
77 Liu, J., Kuang, F., Kroemer, G., Klionsky, D. J., Kang, R. & Tang, D. Autophagy-Dependent Ferroptosis: Machinery and Regulation. Cell Chem Biol 27, 420-435 (2020).
78 Ghosh, S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 88, 102925 (2019).
79 Luo, Y., Fu, X., Han, B., Zhang, F., Yuan, L., Men, H. et al. The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells. Anti-cancer agents in medicinal chemistry 20, 1571–1581 (2020).
80 Ma, X., Mao, G., Chang, R., Wang, F., Zhang, X. & Kong, Z. Down-regulation of autophagy-associated protein increased acquired radio-resistance bladder cancer cells sensitivity to taxol. Int J Radiat Biol 97, 507-516 (2021).
81 Mao, C., Xu, X., Ding, Y. & Xu, N. Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and miRNAs in Bladder Cancer: Implications for Personalized Medicine. Front Med (Lausanne) 8, 735590 (2021).
82 Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y. et al. Regulated Cell Death in Urinary Malignancies. Front Cell Dev Biol 9, 789004 (2021).
83 Samstein, R. M., Lee, C. H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51, 202-206 (2019).
84 Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J. et al. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Rep 20, 1692-1704 (2017).
85 Thompson, L. R., Oliveira, T. G., Hermann, E. R., Chowanadisai, W., Clarke, S. L. & Montgomery, M. R. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity. Int J Mol Sci 21 (2020).
86 El Tekle, G., Bernasocchi, T., Unni, A. M., Bertoni, F., Rossi, D., Rubin, M. A. et al. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends Cancer 7, 823-836 (2021).
87 Zhao, N., Wilkerson, M. D., Shah, U., Yin, X., Wang, A., Hayward, M. C. et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 86, 255-261 (2014).
88 Samulin Erdem, J., Arnoldussen, Y. J., Skaug, V., Haugen, A. & Zienolddiny, S. Copy number variation, increased gene expression, and molecular mechanisms of neurofascin in lung cancer. Mol Carcinog 56, 2076-2085 (2017).
89 Yang, L., Wang, Y. Z., Zhu, H. H., Chang, Y., Li, L. D., Chen, W. M. et al. PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma. DNA Cell Biol 36, 1099-1107 (2017).
90 Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41, 544-552 (2009).
91 Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41, 619-624 (2009).
92 Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
93 Wang, L., Hu, H., Pan, Y., Wang, R., Li, Y., Shen, L. et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 9, e88291 (2014).
94 Manzano, R. G., Catalan-Latorre, A. & Brugarolas, A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer 21, 432 (2021).
95 Neri, F., Rapelli, S., Krepelova, A., Incarnato, D., Parlato, C., Basile, G. et al. Intragenic DNA methylation prevents spurious transcription initiation. Nature 543, 72-77 (2017).
96 Han, J., Wang, J. Z., Yang, X., Yu, H., Zhou, R., Lu, H. C. et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer 18, 110 (2019).
97 Yu, H., Yang, X., Tang, J., Si, S., Zhou, Z., Lu, J. et al. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2alpha-Mediated Glycolysis. Mol Ther Nucleic Acids 23, 27-41 (2021).
98 Tao, L., Mu, X., Chen, H., Jin, D., Zhang, R., Zhao, Y. et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med 11, e310 (2021).
99 Qi, X., Zhang, D. H., Wu, N., Xiao, J. H., Wang, X. & Ma, W. ceRNA in cancer: possible functions and clinical implications. J Med Genet 52, 710-718 (2015).
100 Nicholson, R. I., Gee, J. M., & Harper, M. E.. EGFR and cancer prognosis. European journal of cancer (Oxford, England : 1990) 37, S9–S15 (2001).
101 Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J. et al.. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 105, 12463–12468 (2008).
102 Lin, M. C., Lin, J. J., Hsu, C. L., Juan, H. F., Lou, P. J. & Huang, M. C. GATA3 interacts with and stabilizes HIF-1alpha to enhance cancer cell invasiveness. Oncogene 36, 4243-4252 (2017).
103 Schmucker, H., Blanding, W. M., Mook, J. M., Wade, J. F., Park, J. P., Kwist, K. et al. Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells. Cell Oncol (Dordr) 41, 159-168 (2018).
104 Koren, E. & Fuchs, Y. Modes of Regulated Cell Death in Cancer. Cancer Discov 11, 245-265 (2021).
105 Liang, C., Zhang, X., Yang, M. & Dong, X. Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater 31, e1904197 (2019).
106 Zeng, C., Duan, F., Hu, J., Luo, B., Huang, B., Lou, X. et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol 34, 101523 (2020).
107 Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24, 1550-1558 (2018).
108 Shan, B., Pan, H., Najafov, A., & Yuan, J. Necroptosis in development and diseases. Genes & development 32, 327–340 (2018).
109 Chu, C. E., Sjostrom, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J. et al. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res 27, 5123-5130 (2021).
110 Sjodahl, G., Abrahamsson, J., Holmsten, K., Bernardo, C., Chebil, G., Eriksson, P. et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol 81, 523-532 (2022).